<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880122</url>
  </required_header>
  <id_info>
    <org_study_id>BC-07665</org_study_id>
    <nct_id>NCT04880122</nct_id>
  </id_info>
  <brief_title>Dried Blood Spots for SARS-CoV-2 Serology (COVID-19).</brief_title>
  <official_title>Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 2 Antibodies in a Population of Nursing Home Residents.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to validate dried blood spots (DBS) for SARS-CoV-2 (Severe Acute Respiratory&#xD;
      Syndrome 2) antibody detection in elderly individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the current SARS-CoV-2 pandemic, testing for SARS-CoV-2 specific antibodies is paramount&#xD;
      to monitor immune responses in post-authorization vaccination and sero-epidemiology studies.&#xD;
      However, large scale and iterative serological testing by venipuncture in older persons can&#xD;
      be challenging. Capillary blood sampled using a finger prick and collected on protein saver&#xD;
      cards, i.e., dried blood spots (DBS), has already proven to be a promising alternative.&#xD;
      However, elderly persons have a reduced cutaneous microvasculature, which may affect&#xD;
      DBS-based antibody testing. Therefore, we aimed to evaluate the performance of DBS for the&#xD;
      detection of SARS-CoV-2 antibodies in nursing homes residents. We collected venous blood and&#xD;
      paired Whatman and EUROIMMUN DBS from nursing home residents, and from staff as a reference&#xD;
      population. Venous blood samples were analyzed for the presence of SARS-CoV-2 IgG antibodies&#xD;
      using the Abbot chemiluminescent microparticle immunoassay (CMIA). DBS were analyzed by the&#xD;
      EUROIMMUN enzyme-linked immuno sorbent assay (ELISA) for SARS-CoV-2 IgG antibodies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of DBS for SARS-CoV-2 antibody detection</measure>
    <time_frame>baseline (single timepoint)</time_frame>
    <description>Sensitivity and specificity analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimization of the cut-off for seropositivity.</measure>
    <time_frame>baseline (single timepoint)</time_frame>
    <description>Optimization of the manufacturer recommended cut-off for seropositivity in DBS.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Nursing home residents/staff members</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched venous blood/dried blood spots collection in a single arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dried blood spot and venous blood collection</intervention_name>
    <description>A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).</description>
    <arm_group_label>Nursing home residents/staff members</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  nursing home staff and residents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not applicable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piet Cools</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Ghent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>serology</keyword>
  <keyword>dried blood spot</keyword>
  <keyword>elderly</keyword>
  <keyword>nursing home residents</keyword>
  <keyword>COVID-19</keyword>
  <keyword>antibodies</keyword>
  <keyword>immunoglobins</keyword>
  <keyword>serosurveillance</keyword>
  <keyword>vaccination</keyword>
  <keyword>enzyme-linked immunosorbent assay (ELISA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

